Currentblue cross blue shield - louisianaPolicy AHS - G2120 - Salivary Hormone Testing

Salivary Hormone Testing

Customize your policy alerts

Sign up for blue cross blue shield - louisiana Policy AHS - G2120 - Salivary Hormone Testing alerts

Get alerted when Policy AHS - G2120 - Salivary Hormone Testing changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines coverage stance for salivary hormone tests (including late-night salivary cortisol and other salivary steroid panels) for Blue Cross Blue Shield of Louisiana members, specifying indications that meet or do not meet coverage criteria.

Policy Summary

Payerblue cross blue shield - louisiana

PolicySalivary Hormone Testing

Policy CodePolicy AHS - G2120 - Salivary Hormone Testing

Change TypeNo material change

Effective DateAug 1, 2026

Last ReviewAug 1, 2026

Next Review Date

Key ActionFor suspected Cushing syndrome, obtain at least two late-night salivary cortisol (LNSC) measurements and document signs/symptoms as part of first-line biochemical testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

CoveredLNSC coverage

MultipleNoncovered indications

Validity issuesAssay concerns

4 listedProcedure codes

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Currentblue cross blue shield - louisianaPolicy AHS - G2120 - Salivary Hormone Testing

Salivary Hormone Testing

Customize your policy alerts

Sign up for blue cross blue shield - louisiana Policy AHS - G2120 - Salivary Hormone Testing alerts

Get alerted when Policy AHS - G2120 - Salivary Hormone Testing changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payerblue cross blue shield - louisiana

PolicySalivary Hormone Testing

Policy CodePolicy AHS - G2120 - Salivary Hormone Testing

Change TypeNo material change

Effective DateAug 1, 2026

Last ReviewAug 1, 2026

Next Review Date

Key ActionFor suspected Cushing syndrome, obtain at least two late-night salivary cortisol (LNSC) measurements and document signs/symptoms as part of first-line biochemical testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

CoveredLNSC coverage

MultipleNoncovered indications

Validity issuesAssay concerns

4 listedProcedure codes

08/01/2026Last review

Coverage Criteria

inv-01: LNSC — Medically Necessary

Covered when ALL of the following are met:

LNSC for Cushing syndrome: Individual has signs or symptoms suggestive of Cushing syndrome AND late-night salivary cortisol (LNSC) is ordered as part of first-line biochemical evaluationTwo LNSC measurements recommended; diagnosis established when at least two different first-line tests are abnormal

LNSC is a first-line diagnostic test per clinical guidelines and should be obtained at least twice; two abnormal different first-line tests (e.g., LNSC and 24-hour urinary free cortisol) are required to establish the diagnosis.

inv-02: Not Medically Necessary — Multiple Indications

Not covered for the following indications:

Non–evidence-based salivary panels: Salivary hormone testing for screening, diagnosis, or monitoring of menopause, infertility, endometriosis, polycystic ovary disease (PCOS), premenstrual syndrome (PMS), osteoporosis, sexual dysfunction, seasonal affective disorder, depression, multiple sclerosis, sleep disorders, or diseases related to agingN/A

These uses do not meet coverage criteria due to lack of supporting published evidence and concerns about analytical validity and within-patient variability; proprietary commercial panels (immunoassay-based) have demonstrated poor validity for many sex steroids compared with LC-MS/MS.

inv-03: Covered and not recommended uses

Coverage stance and clinically supported uses:

Society recommendations against salivary testing for HT: Professional societies (ACOG/ASRM, NAMS, Endocrine Society) state that salivary hormone testing is inaccurate, not standardized, and unreliable for assessing or adjusting menopausal hormone therapy or compounded hormone dosingN/A

These society statements support noncoverage for testing intended to guide menopausal or compounded hormone therapy; salivary and urine hormone testing to determine dosing are considered unreliable and not recommended.

Diagnostic role for cortisol disorders: Late-night salivary cortisol (LNSC) may be used in the diagnostic evaluation for Cushing syndrome as a first-line test>=2 measurements

Endocrine Society and guideline evidence recommend obtaining at least two LNSC measurements; diagnosis of Cushing syndrome requires at least two different abnormal first-line tests (e.g., LNSC and 24-hour urinary free cortisol).

Salivary hormone testing for the purpose of individualized dosing of menopausal hormone therapy, including compounded hormone therapy, is excluded because available evidence and specialty society guidance do not support its accuracy or clinical utility. ACOG/ASRM and NAMS have concluded that salivary measurements are neither accurate nor precise for guiding therapy and that intra‑patient variability and methodological limitations prevent reliable dose adjustment. As a result, requests that seek to use salivary hormone results to set or change menopausal hormone dosing will not meet coverage criteria.

Salivary and urine hormone testing to determine dosing of menopausal hormone therapy or compounded hormone therapy is considered unreliable and not recommended. Multiple professional organizations (ACOG/ASRM, NAMS, and AACE statements cited) note that salivary assays lack standardization, show poor correlation with serum and tissue levels, and are affected by pharmacokinetics, diurnal variation, and other patient factors. The policy therefore treats salivary and urine hormone assays as inappropriate methods for dose determination of menopausal or compounded hormone therapy.

Broad salivary hormone panels marketed for so‑called personalized or “bioidentical” hormone therapy, or promoted for screening and monitoring of menopause, infertility, PCOS, PMS, osteoporosis, neuropsychiatric disorders, sleep disorders, or aging‑related conditions, are considered not medically necessary. The scientific background and analytical validity sections indicate these proprietary multi‑analyte panels frequently rely on immunoassays with limited standardization, demonstrate poor correlation with serum, and lack evidence of clinical benefit for these screening or monitoring uses.

Using salivary hormone testing to tailor, adjust, or monitor ongoing hormone therapy (including compounded bioidentical hormones) is considered not medically necessary. The Endocrine Society, NAMS, and other professional groups explicitly advise against salivary hormone testing for monitoring HT because assays are not standardized, lack accepted reference ranges, and there is no demonstrated relationship between salivary hormone levels and clinical outcomes; such testing may therefore lead to inappropriate treatment changes and unnecessary expense.

Coding and Procedure Codes

Applicable CPT/HCPCS Procedure Codesmixed

82530	Cortisol; free
82533	Cortisol; total
S3650	Saliva test, hormone level; during menopause
0462U	Melatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva, screening/preliminary Proprietary Test: Salimetrics® Salivary Melatonin Profile

LNSC diagnostic cutoffs reported

Bedtime cutoff in children (LC-MS/MS)2.4 nmol/L (bedtime salivary cortisol cutoff derived from Ueland et al. for screening Cushing syndrome in children)

Concordance threshold with 24‑hour urine≥ 4 nmol/L showed 97% concordance with 24‑hour urinary free cortisol; tests were considered equivalent at 4 nmol/L

Reported high-sensitivity cutoff2.4 nmol/L reported in a study with 100% sensitivity and 98% specificity at that threshold

Post‑cosyntropin cutoff for adrenal insufficiency exclusion≥ 12.6 nmol/L salivary cortisol at 60 minutes post‑cosyntropin (Kvam Hellan et al.) — used to rule out AI with ~89% diagnostic accuracy

Provider Actions and Prior Authorization

Prior Authorization

Prior authorization required — LNSC only for suspected Cushing syndrome

Late‑night salivary cortisol (LNSC) testing requires prior authorization when ordered for individuals with signs or symptoms of Cushing syndrome because LNSC meets coverage criteria only for that indication; other salivary hormone panels do not meet coverage. Authorization requests should reference that LNSC is being used as part of first‑line biochemical evaluation for suspected Cushing syndrome.

LNSC meets coverage criteria for individuals with signs or symptoms of Cushing syndrome.
Other salivary hormone testing indications do not meet coverage criteria.

Prior Authorization

Confirm prior authorization for listed procedure codes

Verify payer‑specific prior authorization requirements for salivary hormone procedure codes listed in the policy before submitting testing orders or claims.

Applicable procedure codes include 82530, 82533, S3650, and 0462U.
Procedure codes in the policy are provided as a general reference and may not be all‑inclusive.

Background

Salivary testing is a noninvasive approach proposed to measure the free (unbound) fraction of steroid hormones such as cortisol, estrogens, progesterone, and androgens. Cortisol diffuses into saliva and late‑night salivary cortisol (LNSC) is an established first‑line test in the diagnostic evaluation for Cushing syndrome when obtained according to guideline recommendations. However, for many other steroid hormones (notably estradiol and testosterone), salivary measurements show poor correlation with serum, high within‑patient variability, and inconsistent assay performance. Analytical methods vary across proprietary panels (immunoassays versus LC‑MS/MS), and lack of standardization and reference ranges limits clinical interpretation, which is why professional societies recommend against routine salivary hormone testing for individualized dosing or broad screening applications.

Definitions

Late‑night salivary cortisol (LNSC) — definition

TermLate‑night salivary cortisol (LNSC)

DefinitionA salivary cortisol measurement collected late at night used in the diagnostic workup for Cushing syndrome; societies recommend obtaining at least two LNSC measurements for diagnosis

Clinical roleConsidered a first‑line biochemical test for Cushing syndrome when collected per guideline recommendations

LC‑MS/MS — definition and analytical note

TermLC‑MS/MS (Liquid chromatography with tandem mass spectrometry)

Analytical advantageMore reliable than immunoassays for quantifying salivary sex steroids and cortisol; preferred method in diagnostic studies cited

Policy Summary

Payerblue cross blue shield - louisiana

PolicySalivary Hormone Testing

Policy CodePolicy AHS - G2120 - Salivary Hormone Testing

Change TypeNo material change

Effective DateAug 1, 2026

Last ReviewAug 1, 2026

Next Review Date

Key ActionFor suspected Cushing syndrome, obtain at least two late-night salivary cortisol (LNSC) measurements and document signs/symptoms as part of first-line biochemical testing.

SourceLink

On This Page

Step Therapy

Testing pathway — use LNSC as first‑line test and confirm with additional first‑line tests

Follow the recommended testing pathway for suspected Cushing syndrome: use late‑night salivary cortisol (LNSC) as a first‑line diagnostic test, obtain at least two LNSC measurements, and interpret results alongside other first‑line tests (for example, 24‑hour urinary free cortisol or overnight dexamethasone suppression). A diagnosis is established when at least two different first‑line tests are abnormal.

Obtain LNSC measurements at least twice because hypercortisolism may be variable.
Diagnosis of Cushing syndrome requires at least two abnormal first‑line tests (e.g., LNSC plus 24‑hour urinary cortisol).

Documentation Required

Provider documentation — clinical rationale and sample timing

Document clinical rationale and testing details for salivary hormone orders: include signs and symptoms suggestive of hypercortisolism and note that LNSC is being used as part of first‑line evaluation for Cushing syndrome; include number and timing of samples obtained.

Record signs/symptoms of Cushing syndrome in the medical record when ordering LNSC.
Indicate that multiple (at least two) late‑night salivary samples were obtained as part of the evaluation.

Documentation Required

Documentation expectations for LNSC use

When ordering or submitting claims for LNSC, document signs/symptoms of hypercortisolism and obtain at least two late‑night salivary cortisol measurements; two abnormal first‑line tests are required to establish the diagnosis of Cushing syndrome.

Document specific signs and symptoms of hypercortisolism in the chart.
Obtain and record at least two LNSC measurements as part of first‑line biochemical testing.

Billing Rule

Claims and test validation — include procedure code and clinical documentation

Include the specific procedure code when submitting claims for salivary hormone assays and provide clinical documentation supporting medical necessity; note that laboratory‑developed tests (LDTs) must be validated in‑house under CLIA and are not FDA‑approved.

List the applicable CPT/HCPCS code on the claim (e.g., 82530, 82533, S3650, 0462U).
Attach clinical documentation that supports medical necessity for the test.
If the laboratory uses an LDT, be aware it is validated under CLIA but not FDA‑approved.

Denial Risk

Excluded indications — salivary hormone testing not covered for listed conditions

Do not submit or expect coverage for requests for salivary hormone testing when the indication is screening, diagnosis, or monitoring of menopause, infertility, endometriosis, PCOS, PMS, osteoporosis, sexual dysfunction, seasonal affective disorder, depression, multiple sclerosis, sleep disorders, or aging‑related diseases; such requests are excluded and would be denied.

Excluded indications include menopause, infertility, endometriosis, PCOS, premenstrual syndrome, osteoporosis, sexual dysfunction, seasonal affective disorder, depression, multiple sclerosis, sleep disorders, and aging‑related diseases.
Coverage is limited to LNSC for suspected Cushing syndrome.

Denial Risk

High denial risk — salivary testing for HT dosing or monitoring

Testing intended to adjust hormone dosing or to monitor menopausal hormone therapy (including compounded bioidentical hormones) is considered unreliable by specialty societies and is at high risk for denial when billed for medical necessity.

Professional societies (ACOG/ASRM, NAMS, Endocrine Society) state salivary testing is inaccurate, not standardized, and unreliable for adjusting or monitoring hormone therapy.
Requests to guide menopausal hormone therapy dosing or monitor compounded HT are likely to be denied as not medically necessary.

Use in studiesUsed to derive bedtime cutoffs and validate diagnostic accuracy for LNSC and post‑cosyntropin salivary cortisol

Late‑night salivary cortisol — society recommendations and sampling note

Society recommendationsEndocrine Society, ACOG/ASRM, and NAMS state salivary hormone assays are not standardized, lack accepted reference ranges, and recommend against using salivary testing to assess or monitor hormone therapy

Sampling recommendation for LNSCSocieties recommend obtaining at least two late‑night salivary cortisol measurements for diagnosis of Cushing syndrome; late‑night salivary or serum cortisol may be used post‑TSS to assess eucortisolism

Limitations notedSocieties note no demonstrated correlation between symptoms and salivary hormone levels and cite lack of independent quality control programs

Laboratory‑developed test (LDT) — definition and regulatory note

DefinitionLaboratory‑developed test (LDT): a test developed and validated in‑house by a laboratory and regulated under CLIA as a high‑complexity test; not FDA approved

Regulatory noteLDTs must be validated and performed in the laboratory under CLIA '88; FDA clearance/approval is not required for clinical use although LDTs are not FDA‑approved

Claim submission implicationWhen submitting claims include the specific procedure code and clinical documentation; LDTs used must be validated in‑house per CLIA